Intrastromal injection of bevacizumab in patients with corneal neovascularization

被引：15
|
作者：
Cabreira Vieira, Ana Carolina [1 ]
Hoefling-Lima, Ana Luisa [1 ]
Gomes, Jose Alvaro P. [1 ]
de Freitas, Denise [1 ]
Farah, Michel Eid [1 ]
Belfort, Rubens, Jr. [1 ]
机构：
[1] Univ Fed Sao Paulo UNIFESP, Vis Inst, Dept Ophthalmol, Sao Paulo, Brazil
来源：
ARQUIVOS BRASILEIROS DE OFTALMOLOGIA | 2012年 / 75卷 / 04期
关键词：
Corneal stroma/drug effects; Corneal neovascularization/drug therapy; Injections; intraocular; Antibodies; monoclonal/administration; dosage; INTRAVITREAL BEVACIZUMAB; ANGIOGENESIS; LYMPHANGIOGENESIS; SUBCONJUNCTIVAL; AVASTIN;
D O I：
10.1590/S0004-27492012000400012
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
Corneal neovascularization (NV) not only reduces visual acuity, but it also causes loss of the cornea's immune privilege, strongly contributing to a worse prognosis in penetrating keratoplasty. Several mediators participate in corneal angiogenesis, and the role of vascular endothelial growth factor (VEGF) has been extensively proven. Anti-VEGF agents have been shown to be effective in slowing the growth of corneal neovessels. Bevacizumab, an anti-VEGF agent, has been successfully used in the treatment of corneal neovascularization. In this paper, we report a series of patients who underwent intracorneal bevacizumab injections to treat corneal vascularization.
引用
收藏
页码：277 / 279
页数：3
相关论文
共 50 条
  • [11] Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium
    Bahar, Irit
    Kaiserman, Igor
    McAllum, Penny
    Rootman, David
    Slomovic, Allan
    CURRENT EYE RESEARCH, 2008, 33 (01) : 23 - 28
  • [12] Intrastromal Aflibercept for the Treatment of Corneal Neovascularization
    Mergen, Burak
    Dogan, Cezmi
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [13] Bevacizumab for Corneal Neovascularization
    Jacobs, Deborah S.
    Lim, Mira
    Carrasquillo, Karen G.
    Rosenthal, Perry
    OPHTHALMOLOGY, 2009, 116 (03) : 592 - 593
  • [14] The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization
    Acar, Banu Torun
    Halili, Elvin
    Acar, Suphi
    INTERNATIONAL OPHTHALMOLOGY, 2013, 33 (05) : 507 - 513
  • [15] Subconjunctival and Intracorneal Bevacizumab Injection for Corneal Neovascularization in Lipid Keratopathy
    Oh, Joo Youn
    Kim, Mee Kum
    Wee, Won Ryang
    CORNEA, 2009, 28 (09) : 1070 - 1073
  • [16] Combined Use of Subconjunctival and Intracorneal Bevacizumab Injection for Corneal Neovascularization
    Yeung, Sonia N.
    Lichtinger, Alejandro
    Kim, Peter
    Amiran, Maoz D.
    Slomovic, Allan R.
    CORNEA, 2011, 30 (10) : 1110 - 1114
  • [17] The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization
    Banu Torun Acar
    Elvin Halili
    Suphi Acar
    International Ophthalmology, 2013, 33 : 507 - 513
  • [18] Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization
    You, In-Cheon
    Kang, In-Seong
    Lee, Seung-Hyun
    Yoon, Kyung-Chul
    ACTA OPHTHALMOLOGICA, 2009, 87 (06) : 653 - 658
  • [19] A randomized study of subconjonctival bevacizumab (Avastin ® ) injection for corneal neovascularization
    Rocher, M.
    Benayoun, Y.
    Quilbe, S.
    Laribi, S.
    Fournie, P.
    Leveziel, N.
    Trone, M. -c.
    Bourcier, T.
    Robert, P. -y.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2024, 47 (05):
  • [20] Effectiveness of photodynamic therapy with verteporfin combined with intrastromal bevacizumab for corneal neovascularization in Stevens–Johnson syndrome
    Hyeon Jeong Yoon
    Mee Kum Kim
    Kyung Yul Seo
    Mayumi Ueta
    Kyung Chul Yoon
    International Ophthalmology, 2019, 39 : 55 - 62
12345